<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00630682</url>
  </required_header>
  <id_info>
    <org_study_id>25.139</org_study_id>
    <secondary_id>P50DA018179</secondary_id>
    <nct_id>NCT00630682</nct_id>
  </id_info>
  <brief_title>A Pilot Trial of Dextroamphetamine for Methamphetamine Dependence</brief_title>
  <acronym>1D</acronym>
  <official_title>A Pilot Trial of Dextroamphetamine for Methamphetamine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>California Pacific Medical Center Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>California Pacific Medical Center Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and effectiveness dextroamphetamine to help
      methamphetamine users quit or cut down on their use. The study lasts for 9 weeks. Eligible
      participants will attend research visits twice per week, and will receive individual
      counseling sessions once per week for all 9 weeks. 50% of the participants will receive the
      active medication while the other 50% will receive the placebo (sugar pill). Neither the
      participant or the study team will know if the participant is receiving the placebo or active
      drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects treated with dextroamphetamine will have better outcomes than subjects treated with placebo, as indicated by the number of urine samples that do not indicate new use of MA (the primary outcome measure)</measure>
    <time_frame>Twice per week for 8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Methamphetamine Addiction</condition>
  <arm_group>
    <arm_group_label>Dextroamphetamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextroamphetamine</intervention_name>
    <description>1 week placebo and 8 weeks 60mg d-AMP QD.</description>
    <arm_group_label>Dextroamphetamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>9 weeks of placebo 60mg capsules QD.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-50 yrs. old

        Exclusion Criteria:

          -  pregnant or lactating females

               -  Contact site for additional information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gantt Galloway, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Addiction Pharmacology Research Laboratory</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CPMC-St. Luke's Campus-Addiction Pharmacology Research Laboratory</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2008</study_first_posted>
  <last_update_submitted>May 30, 2013</last_update_submitted>
  <last_update_submitted_qc>May 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>California Pacific Medical Center Research Institute</investigator_affiliation>
    <investigator_full_name>Gantt Galloway, PharmD</investigator_full_name>
    <investigator_title>Scientist</investigator_title>
  </responsible_party>
  <keyword>Methamphetamine</keyword>
  <keyword>Drug Abuse</keyword>
  <keyword>Drug Treatment</keyword>
  <keyword>Addiction</keyword>
  <keyword>Meth</keyword>
  <keyword>Treatment for Methamphetamine Dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behavior, Addictive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methamphetamine</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

